Pharming Group N.V. (PHAR) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $12.62 (-1.52%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 10, 2026 | Whitney Ijem | Canaccord Genuity | $37.00 | +193.2% |
| Mar 12, 2026 | Joseph Pantginis | H.C. Wainwright | $37.00 | +193.2% |
| Dec 9, 2024 | Lucy Codrington | Jefferies | $14.00 | +10.9% |
Top Analysts Covering PHAR
PHAR vs Sector & Market
| Metric | PHAR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 2 | 8 | 19 |
| Target Upside | +196.8% | +11474.8% | +17.1% |
| P/E Ratio | 72.11 | 3.84 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $100M | $103M | $106M | 2 |
| 2026-09-30 | $105M | $108M | $111M | 1 |
| 2026-12-31 | $110M | $113M | $116M | 1 |
| 2027-12-31 | $381M | $416M | $452M | 3 |
| 2028-12-31 | $360M | $385M | $415M | 1 |
| 2029-12-31 | $428M | $457M | $493M | 2 |
| 2030-12-31 | $658M | $702M | $758M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.04 | $0.04 | $0.04 | 2 |
| 2026-09-30 | $0.05 | $0.05 | $0.05 | 1 |
| 2026-12-31 | $0.06 | $0.06 | $0.06 | 1 |
| 2027-12-31 | $0.16 | $0.37 | $0.56 | 2 |
| 2028-12-31 | $0.41 | $0.44 | $0.49 | 1 |
| 2029-12-31 | $0.52 | $0.56 | $0.62 | 1 |
| 2030-12-31 | $0.78 | $0.84 | $0.93 | 1 |
Frequently Asked Questions
What is the analyst consensus for PHAR?
The consensus among 2 analysts covering Pharming Group N.V. (PHAR) is Buy with an average price target of $38.00.
What is the highest price target for PHAR?
The highest price target for PHAR is $37.00, set by Whitney Ijem at Canaccord Genuity on 2026-04-10.
What is the lowest price target for PHAR?
The lowest price target for PHAR is $14.00, set by Lucy Codrington at Jefferies on 2024-12-09.
How many analysts cover PHAR?
2 analysts have issued ratings for Pharming Group N.V. in the past 12 months.
Is PHAR a buy or sell right now?
Based on 2 analyst ratings, PHAR has a consensus rating of Buy (2.00/5) with a +196.8% upside to the consensus target of $38.00.
What are the earnings estimates for PHAR?
Analysts estimate PHAR will report EPS of $0.04 for the period ending 2026-06-30, with revenue estimated at $103M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.